RxDoctor Payments Data

Andrew Bailey, MD

Glaucoma Specialist · Oklahoma City, OKNPI 1285772160

Payments from drug & device makers

$2,712in general payments, 2019–2025

Across 42 payments — averaging $64.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nova Eye, Inc.$2K
  • Sight Sciences, Inc.$178
  • Ivantis, Inc$137
  • Novartis$116
  • Alcon$114
  • Iridex Corporation$107
  • plus $560 from 11 others

What the payments were for

  • Consulting fees$1,50055%
  • Travel & lodging$1074%
  • Food & beverage$1,10541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$260,153
Medicare patients
738
Services billed
2,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate124$52,651
LumiganBimatoprost82$32,205
Prednisolone Acetate294$14,447
Latanoprost1,244$14,400
SimbrinzaBrinzolamide/Brimonidine Tart49$13,126
Brimonidine Tartrate556$12,956
Travoprost67$12,547
RestasisCyclosporine17$10,225
CombiganBrimonidine Tartrate/Timolol26$9,777
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat591$8,953
Ketorolac Tromethamine206$7,278
Alphagan PBrimonidine Tartrate18$6,099
Loteprednol Etabonate30$5,917
Timolol Maleate425$4,997
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$4,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$84$58,306143 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$81$56,849135 claims
AlconSimbrinza$114$13,12649 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$42$5,91730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →